Abstract
A 71-year old female patient with inferior ST-elevation myocardial infarction underwent primary percutaneous coronary intervention (PCI) within 3 h of symptom onset. She was preloaded with 300 mg aspirin and 600 mg clopidogrel before PCI. Coronary angiogram showed occlusion of the right coronary artery. During PCI, eptifibatide was initiated due to the large thrombus burden. Few hours after the procedure, on eptifibatide infusion, a severe drop in platelet count was observed (from 210,000/μl to 35,000/μl) and the infusion was discontinued. One hour later, still under eptifibatide effect and with severe thrombocytopenia, acute stent thrombosis developed. Lack of prior heparin exposure, quick onset of thrombocytopenia made heparin induced thrombocytopenia improbable that was later excluded by specific immunoassay. However, platelet function testing suggested that eptifibatide induced thrombocytopenia was mediated by activating autoantibodies since platelet reactivity was paradoxically very high at the time of stent thrombosis but decreased radically with eptifibatide washout. The patient was successfully managed without further complications on the basis of platelet function data obtained in the subsequent days. This rare subtype of thrombocytopenia highlights that not only platelet count but also platelet function should be closely monitored in case of severe thrombocytopenia to better balance bleeding and thrombosis.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11239-015-1270-y/MediaObjects/11239_2015_1270_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11239-015-1270-y/MediaObjects/11239_2015_1270_Fig2_HTML.gif)
Similar content being viewed by others
References
Hu Y, Yuan M, Lu X (2013) Thrombocytopenia induced by both aspirin and clopidogrel in the same patient. Int J Clin Pharmacol Ther 51:228–231
Arepally GM, Ortel TL (2006) Heparin-induced thrombocytopenia. N Engl J Med 355:809–817
Aster RH (2005) Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127:53–59
Morel-Kopp MC, Tan CW, Brighton TA, McRae S, Baker R, Tran H, Mollee P, Kershaw G, Joseph J, Ward C, ASTH Clinical Trials Group (2012) Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thromb Haemost 107:575–583
Giuliano C, Edwin SB, Kador H, Mooney M (2012) Eptifibatide-induced thrombocytopenia and subsequent thrombosis. J Pharm Technol 28:146–150
Tempelhof MW, Benzuly KH, Fintel D, Krichavsky MZ (2012) Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Tex Heart Inst J 39:86–91
Epelman S, Nair D, Downey R, Militello M, Askari AT (2006) Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thromb 22:151–154
Gao C, Boylan B, Bougie D, Gill JC, Birenbaum J, Newman DK, Aster RH, Newman PJ (2009) Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain. J Clin Invest 119:504–511
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dániel Aradi: Consulting for Verum Diagnostica GmbH, Lecture fees from AstraZeneca, DSI/Lilly, Verum Diagnostica, Roche Diagnostics. Other authors report no declarations of interest.
Rights and permissions
About this article
Cite this article
Dézsi, D.A., Bokori, G., Faluközy, J. et al. Eptifibatide-induced thrombocytopenia leading to acute stent thrombosis. J Thromb Thrombolysis 41, 522–524 (2016). https://doi.org/10.1007/s11239-015-1270-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-015-1270-y